Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.9 kDa. The protein migrates as 45-55 kDa under reducing (R) condition, and 90 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>98% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CTLA-4, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98%.
The purity of Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) is more than 90% and the molecular weight of this protein is around 82-100 kDa verified by SEC-MALS.
Immobilized Human B7-2, His Tag (Cat. No. CD6-H5223) at 10 μg/mL (100 μL/well) can bind Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) with a linear range of 2-78 ng/mL (QC tested).
Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 10 μg/mL (100 μL/well) can bind Human B7-1, His Tag (Cat. No. B71-H5228) with a linear range of 0.156-1.25 μg/mL (Routinely tested).
Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.8260 μg/mL (Routinely tested).
Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 μg/mL (Routinely tested).
Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 0.52 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 1.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadonilimab | AK-104; AK104 | Approved | Zhongshan Akeso Biopharma Co Ltd | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Microsatellite instability-high cancer; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Mismatch Repair Deficient Cancer; Carcinoma; Vaginal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms; Lymphoma, T-Cell, Peripheral | Details |
Ipilimumab | 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010 | Approved | Bristol-Myers Squibb Company | Yervoy, 逸沃 | United States | Melanoma | Bristol-Myers Squibb Company | 2011-03-25 | Ovarian germ cell tumor; Liver Neoplasms; Leukemia, Myelogenous, Chronic; Ovarian Neoplasms; Solid tumours; Intestinal Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Skin Melanoma; Lymphoma, T-Cell, Peripheral; HIV Infections; Teratoma; Fibromatosis, Aggressive; Cystadenocarcinoma; Carcinoma, Renal Cell; Leukemia, Hairy Cell; Hemangiosarcoma; Carcinoma, Merkel Cell; Rectal Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Parathyroid Neoplasms; Pheochromocytoma; Cystadenocarcinoma, Serous; Carcinoma, Basal Cell; Cystadenocarcinoma, Mucinous; Anus Neoplasms; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Carcinoma, Transitional Cell; Seminoma; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Colonic Neoplasms; Lymphoma, Large-Cell, Immunoblastic; Myeloproliferative Disorders; Carcinoma, Verrucous; Hodgkin Disease; Papillomavirus Infections; Pancreatic Neoplasms; Carcinoma, Ovarian Epithe | Details |
Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Hepatocellular | Astrazeneca Ab | 2022-10-21 | Testicular Neoplasms; Esophageal adenocarcinoma; Gallbladder Neoplasms; Urogenital Neoplasms; Fallopian Tube Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Pinealoma; Genital Neoplasms, Female; Oropharyngeal Neoplasms; Mouth Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Urethral Neoplasms; Vulvar Neoplasms; Sarcoma; Microsatellite Instability; Cholangiocarcinoma; Breast Neoplasms; Melanoma; Laryngeal Diseases; Adenocarcinoma; Carcinoma, Endometrioid; Dysgerminoma; Uterine Cervical Neoplasms; Hepatitis C, Chronic; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Metastatic breast cancer; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Bone metastases; Cystadenoma, Serous; Vaginal Neoplasms; Digestive System Diseases; Carcinoma, Merkel Cell; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; C | Details |
Iparomlimab/Tuvonralimab | PBS-103/PBS-105; QL-1706; PSB-205 | Approved | Qilu Pharmaceutical Co Ltd | 齐倍安 | Mainland China | Uterine Cervical Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-09-26 | Colonic Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CS-1002 | CS-1002; SHR-8068 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Bile Duct Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Botensilimab | AGEN-1181 | Phase 3 Clinical | Agenus Inc | Neoplasms; Uterine Cervical Neoplasms; Neoplasm Metastasis; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite Instability; Solid tumours; Colonic Neoplasms; Pancreatic Neoplasms; Fibrolamellar hepatocellular carcinoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Hemangiosarcoma; Liver Neoplasms; Ovarian Neoplasms | Details |
RP-2 | RP-2 | Phase 3 Clinical | Replimune Group Inc | Neoplasms; Uveal melanoma; Colorectal Neoplasms; Precancerous Conditions | Details |
Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Sarcoma; Prostatic Neoplasms; Carcinoma, Adenoid Cystic; Solid tumours; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Anorectal disorders; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
Erfonrilimab | KN-046; KN046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Colorectal Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Lymphoma; Thymoma; Thymus Neoplasms; Solid tumours; Breast Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms | Details |
Volrustomig | MEDI-5752; MEDI5752 | Phase 3 Clinical | Medimmune Llc | Biliary Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Skin Melanoma; Melanoma | Details |
Ipilimumab biosimilar (Innovent Biologics) | IBI-310 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Mismatch Repair Deficient Cancer; Colonic Neoplasms; Neuroendocrine Tumors; Microsatellite Instability; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
YH-001 | YH-001 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Alopecia Areata; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
BMS-986288 | BMS-986288 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | Bioatla, BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Vudalimab | XmAb-20717; XmAb-717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Thymoma; Adenocarcinoma, Clear Cell; Vulvar Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Astrocytoma; Castration-Sensitive Prostate Neoplasms; Carcinoma, Neuroendocrine; Prostatic Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Hodgkin Disease; Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Adenoma, Acidophil; Mesothelioma; Microsatellite instability-high cancer; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant | Details |
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Genetic Engineering Co Ltd | Melanoma | Details | |
Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Ovarian Clear Cell Carcinoma; Carcinoma, Renal Cell; Solid tumours; Skin Melanoma | Details |
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
Quavonlimab | AK-107; MK-1308 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody, Ludwig Institute For Cancer Research | Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Hemangiosarcoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Prostatic Neoplasms, Castration-Resistant; Adrenal Gland Neoplasms; Prostatic Neoplasms; Lung Neoplasms | Details |
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd | Solid tumours; Liver Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Carcinoma, Merkel Cell; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Solid tumours; Neoplasms; Neuroendocrine Tumors; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Thyroid Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Pancreatic Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell | Details |
Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Vulvar Neoplasms; Sarcoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours | Details |
EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Solid tumours; Neoplasms | Details |
COYA-302 | COYA302; COYA 302; COYA-302 | Phase 2 Clinical | Coya Therapeutics Inc | Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
GI-102 | GI-102 | Phase 2 Clinical | GI Innovation Inc | Skin Melanoma; Ovarian Neoplasms; Solid tumours; Liver Neoplasms; Carcinoma, Renal Cell; Soft Tissue Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
Vilastobart | XTX-101; XTX101 | Phase 2 Clinical | Xilio Development Inc | Colorectal Neoplasms | Details |
RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Solid tumours; Liver Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
JS-007 | JS007; JS-007 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Lung Neoplasms; Melanoma | Details |
KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Solid tumours | Details |
Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Cholangiocarcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
Ipilimumab biosimilar (Henlius) | HLX13 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
VDJ-142 | VDJ-142 | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Inflammation | Details |
SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours; Neoplasms | Details |
CTLA-4 Mab (Beijng Immunoah Pharma Tech) | 5E3 (Beijng Immunoah Pharma Tech); CTLA-4 Mab (Beijng Immunoah Pharma Tech) | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
CS-2009 | CS-2009 | Phase 1 Clinical | Cstone Pharmaceuticals | Solid tumours; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Solid tumours | Details |
STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Colorectal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms | Details |
KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 1 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | Details |
IMM-27M | IMM-27M; IMM27M; SYN27M; SYN-27M | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms; Pathologic Processes; Carcinoma, Hepatocellular | Details |
Imiquimod/Zalifrelimab | UGN-302; UGN-201+UGN-301 | Phase 1 Clinical | Urogen Pharma | Urinary Bladder Neoplasms | Details |
TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Melanoma | Details |
B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
This web search service is supported by Google Inc.